Now Playing
|Videos|December 27, 2017
Special Considerations in HIV Management
Advertisement
Episodes in this series
Throughout this AJMC Peer Exchange®, a panel of experts in infectious disease and managed care will discuss today’s management of HIV, including the need for individualized care and the role for newer treatment options.
Advertisement
Related to this article
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
2
FDA Approves First Treatment for Sanfilippo Syndrome Type A
3
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
4
Lung Cancer Progress Drives Down US Cancer Death Rates
5